EHA: GENE THERAPY WITH THE LENTIVIRAL VECTOR TNS9.3.55 PRODUCES LONG-TERM IMPROVEMENT IN SEVERE ß-THALASSEMIA

β-thalassemia is the most prevalent monogenic disease for which gene therapy with autologous hematopoietic progenitor cells (HPC) modified to express ß-globin represents apotential therapeutic option.

View the rest of the article here

View the PDF